Locally Advanced or Metastatic Solid Tumors
Precision Imaging.
Targeted Therapy.Measurable Outcomes.
Biogenix Molecular and CIRA Health are advancing clinical research in molecular imaging, theranostics, PET/CT, SPECT/CT, dosimetry, and targeted radiopharmaceutical therapy.
CIRA Health research infrastructureMolecular imaging, trial coordination, and theranostics workflow support.
Identify
Advanced PET imaging detects therapeutic targets including PSMA, SSTR, and GRPR.
Treat
Targeted radioligand therapy delivers focused radiation to cancer cells.
Track
Follow-up imaging supports response assessment and dosimetry-informed care.
Now Enrolling in Clinical Trials
Therapy Response Visualization
Pre-therapy and post-therapy molecular imaging shown for illustrative clinical research education.
786-791-1799Call to learn more
Coral Way Professional Center2760 SW 97th Avenue, Suite B103, Miami, FL 33165
About Biogenix Molecular
A CIRA Health Research Division
Biogenix Molecular is a clinical research division of CIRA Health dedicated to advancing molecular imaging and targeted radiopharmaceutical therapies through innovative clinical trials.
Our Mission
To improve patient outcomes by advancing precision imaging and targeted therapies through world-class research, physician collaboration, and compassionate care.
What We Do
Clinical Trials
Conducting phase 1-3 clinical trials across oncology and molecular imaging.
Theranostics
Combining diagnostic imaging with targeted radioligand therapy.
Patient Care
Collaborating with patients and physicians to improve outcomes.
Research
Advancing science to drive the future of precision medicine.
Our Commitment
We are committed to scientific excellence, patient safety, regulatory integrity, and data quality in every study we conduct.
Theranostics
The Power of Precision
Theranostics pairs molecular imaging with targeted radiopharmaceutical therapy, using the same biologic target to identify disease, deliver therapy, and monitor response over time.
TheranosticsThe Right Target.
The Right Therapy.
The Right Patient.
The Right Therapy.
The Right Patient.
1
IdentifyDetect targets with precision imaging2
TreatDeliver targeted radioligand therapy3
TrackMonitor response with follow-up imagingKey Molecular Targets
PSMA
Prostate Cancer
SSTR
Neuroendocrine Tumors
GRPR
Emerging Targets
FAPI
Solid Tumors
The Theranostic Advantage
Personalized treatment based on your tumor biology
Targets cancer cells while minimizing damage to healthy tissue
Real-time monitoring of treatment response
Improved outcomes and quality of life
Molecular-based patient selection
Quantitative baseline disease burden
Clinical Response
Illustrative pre-treatment and post-treatment PSMA PET imaging response, presented in an enhanced before-and-after comparison graphic.
